OpenAI, Google, Amazon, Microsoft and Anthropic have all launched consumer-facing AI health tools in 2026.
The startup behind AI molecule models used by Lilly, Novartis and Pfizer hits a $3.8 billion valuation.
The partnership targets neuroimmune and CNS disorders using Insilico's Pharma.AI engine, with $18 million in upfront payments and milestone-based upside.
Inductive Bio won the openADMET competition, but a 28-way statistical tie suggests data quality may trump model architecture for predicting…
The alliance extends Insilico's PandaOmics and Chemistry42 platforms into pharmaceutical manufacturing for the first time, targeting a $168B CDMO industry.
In a rare bipartisan move, the senators demand internal records from UnitedHealth, Humana, and CVS on the use of AI…
The OpenADMET challenge found that smaller, specialized models matched or beat large foundation models at predicting how the body processes…
COMPASS, a pan-cancer foundation model, outperforms 22 methods across 16 clinical cohorts by analyzing tumor transcriptomes through immune concepts.